Willow Biosciences Inc Total Liabilities
Willow Biosciences Inc total liabilities. Based on the latest financial reports, Willow Biosciences Inc (WLLW) has total liabilities worth CA$3.00 Million CAD (≈ $2.17 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check WLLW financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Willow Biosciences Inc (1998–2024)
Total liabilities of Willow Biosciences Inc from 1998 to 2024. This chart illustrates how Willow Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore WLLW long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Willow Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Willow Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nippon Active Value Fund Plc
LSE:NAVF
|
UK | GBX671.00K |
|
MEKICS Co Ltd
KQ:058110
|
Korea | ₩19.37 Billion |
|
Protektor S.A.
WAR:PRT
|
Poland | zł39.39 Million |
|
Athena Resources Ltd
AU:AHN
|
Australia | AU$117.32K |
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
USA | $3.87 Million |
|
HIGH QUALITY FOOD
F:L24
|
Germany | €15.27 Million |
|
Me Group International PLC
LSE:MEGP
|
UK | GBX127.43 Million |
|
Better Choice Company Inc
NYSE MKT:BTTR
|
USA | $7.32 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down Willow Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see WLLW asset base.
Liquidity & Leverage Metrics
Willow Biosciences Inc Total Liabilities Ratios Explained
Willow Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Willow Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Willow Biosciences Inc (1998–2024)
The table below shows the annual total liabilities of Willow Biosciences Inc from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$2.99 Million ≈ $2.17 Million |
-7.51% |
| 2023-12-31 | CA$3.24 Million ≈ $2.34 Million |
+82.47% |
| 2022-12-31 | CA$1.77 Million ≈ $1.28 Million |
-66.74% |
| 2021-12-31 | CA$5.33 Million ≈ $3.86 Million |
-76.21% |
| 2020-12-31 | CA$22.42 Million ≈ $16.22 Million |
+88.83% |
| 2019-12-31 | CA$11.87 Million ≈ $8.59 Million |
+8896.06% |
| 2018-12-31 | CA$132.00K ≈ $95.49K |
-84.81% |
| 2017-12-31 | CA$869.19K ≈ $628.76K |
-58.27% |
| 2016-12-31 | CA$2.08 Million ≈ $1.51 Million |
+47.86% |
| 2015-12-31 | CA$1.41 Million ≈ $1.02 Million |
+34.60% |
| 2014-12-31 | CA$1.05 Million ≈ $757.03K |
+10.18% |
| 2013-12-31 | CA$949.86K ≈ $687.12K |
-23.13% |
| 2012-12-31 | CA$1.24 Million ≈ $893.82K |
+140.06% |
| 2011-12-31 | CA$514.71K ≈ $372.33K |
+153.17% |
| 2010-12-31 | CA$203.31K ≈ $147.07K |
-37.11% |
| 2009-12-31 | CA$323.26K ≈ $233.84K |
-64.05% |
| 2008-12-31 | CA$899.22K ≈ $650.48K |
+56.58% |
| 2007-12-31 | CA$574.30K ≈ $415.44K |
-10.81% |
| 2006-12-31 | CA$643.90K ≈ $465.79K |
+10.69% |
| 2005-12-31 | CA$581.73K ≈ $420.82K |
-18.76% |
| 2004-12-31 | CA$716.03K ≈ $517.97K |
-26.99% |
| 2003-12-31 | CA$980.68K ≈ $709.41K |
+27.20% |
| 2002-12-31 | CA$770.95K ≈ $557.70K |
+9.57% |
| 2001-12-31 | CA$703.62K ≈ $508.99K |
+27.73% |
| 2000-12-31 | CA$550.87K ≈ $398.49K |
+113.61% |
| 1999-12-31 | CA$257.88K ≈ $186.55K |
+79.77% |
| 1998-12-31 | CA$143.45K ≈ $103.77K |
-- |
About Willow Biosciences Inc
Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 20… Read more